These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15898742)

  • 1. Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugate.
    Torgov MY; Alley SC; Cerveny CG; Farquhar D; Senter PD
    Bioconjug Chem; 2005; 16(3):717-21. PubMed ID: 15898742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
    Tietze LF; Krewer B
    Chem Biol Drug Des; 2009 Sep; 74(3):205-11. PubMed ID: 19660031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suicide gene therapy using E. coli beta-galactosidase.
    Farquhar D; Pan BF; Sakurai M; Ghosh A; Mullen CA; Nelson JA
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):65-70. PubMed ID: 12111114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
    Svensson HP; Frank IS; Berry KK; Senter PD
    J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.
    Siemers NO; Kerr DE; Yarnold S; Stebbins MR; Vrudhula VM; Hellström I; Hellström KE; Senter PD
    Bioconjug Chem; 1997; 8(4):510-9. PubMed ID: 9258449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensely cytotoxic anthracycline prodrugs: galactosides.
    Bakina E; Farquhar D
    Anticancer Drug Des; 1999 Dec; 14(6):507-15. PubMed ID: 10834272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering.
    McDonagh CF; Beam KS; Wu GJ; Chen JH; Chace DF; Senter PD; Francisco JA
    Bioconjug Chem; 2003; 14(5):860-9. PubMed ID: 13129388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
    Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
    J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates.
    Gesson JP; Jacquesy JC; Mondon M; Petit P; Renoux B; Andrianomenjanahary S; Dufat-Trinh Van H; Koch M; Michel S; Tillequin F
    Anticancer Drug Des; 1994 Oct; 9(5):409-23. PubMed ID: 7945725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates.
    Fang L; Battisti RF; Cheng H; Reigan P; Xin Y; Shen J; Ross D; Chan KK; Martin EW; Wang PG; Sun D
    J Med Chem; 2006 Oct; 49(21):6290-7. PubMed ID: 17034135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Wallace PM; Senter PD
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An improved synthesis of lysosomal activated mustard prodrug for tumor-specific activation and its cytotoxic evaluation.
    Adidala R; Devalapally H; Srivari C; Devarakonda R K; Akkinepally RR
    Drug Dev Ind Pharm; 2012 Sep; 38(9):1047-53. PubMed ID: 22185667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy.
    Tietze LF; von Hof JM; Krewer B; Müller M; Major F; Schuster HJ; Schuberth I; Alves F
    ChemMedChem; 2008 Dec; 3(12):1946-55. PubMed ID: 19021160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.
    Heinis C; Alessi P; Neri D
    Biochemistry; 2004 May; 43(20):6293-303. PubMed ID: 15147213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and enzyme-specific activation of carbohydrate-geldanamycin conjugates with potent anticancer activity.
    Cheng H; Cao X; Xian M; Fang L; Cai TB; Ji JJ; Tunac JB; Sun D; Wang PG
    J Med Chem; 2005 Jan; 48(2):645-52. PubMed ID: 15658879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor.
    Zhang Y; Pardridge WM
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1075-81. PubMed ID: 15718287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and activities of a new melphalan prodrug designed for tumor-selective activation.
    Kerr DE; Li Z; Siemers NO; Senter PD; Vrudhula VM
    Bioconjug Chem; 1998; 9(2):255-9. PubMed ID: 9548542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates.
    Jeffrey SC; Andreyka JB; Bernhardt SX; Kissler KM; Kline T; Lenox JS; Moser RF; Nguyen MT; Okeley NM; Stone IJ; Zhang X; Senter PD
    Bioconjug Chem; 2006; 17(3):831-40. PubMed ID: 16704224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme-catalyzed activation of anticancer prodrugs.
    Rooseboom M; Commandeur JN; Vermeulen NP
    Pharmacol Rev; 2004 Mar; 56(1):53-102. PubMed ID: 15001663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.